Trevi Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Trevi Therapeutics, Inc. filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing financial instruments and key dates.</b>

AI Summary

Trevi Therapeutics, Inc. (TRVI) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Trevi Therapeutics, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing includes data related to common stock, warrants, and pre-funded warrants. Key dates mentioned include October 18, 2021, and August 13, 2020, related to private placements and loans. Fair value measurements for assets like U.S. Treasury Securities and Money Market Funds as of March 31, 2024, are detailed. The company's business address is 195 Church Street, 14th Floor, New Haven, CT 06510.

Why It Matters

For investors and stakeholders tracking Trevi Therapeutics, Inc., this filing contains several important signals. This filing provides investors with an updated view of Trevi Therapeutics' financial position and activities during the first quarter of 2024, including details on equity instruments and debt. Understanding the fair value measurements and the context of private placements and warrants is crucial for assessing the company's capital structure and potential future dilution.

Risk Assessment

Risk Level: low — Trevi Therapeutics, Inc. shows low risk based on this filing. The filing is a standard 10-Q, indicating routine financial reporting with no immediate red flags.

Analyst Insight

Monitor future filings for updates on the company's financial health and strategic initiatives related to its equity and debt instruments.

Key Numbers

• 2024-03-31 — Reporting Period End Date (Conformed Period of Report)
• 2024-05-07 — Filing Date (Filed as of date)
• 2021-10-18 — Private Placement Date (trvi:NewEnterpriseAssociates16LimitedPartnershipMember us-gaap:PrivatePlacementMember)
• 2020-08-13 — Loan Date (trvi:SiliconValleyBankTermLoanMember)

Key Players & Entities

• Trevi Therapeutics, Inc. (company) — Filer
• 0000950170-24-054489 (other) — Accession Number
• 2024-03-31 (date) — Conformed Period of Report
• 2024-05-07 (date) — Filed as of date
• 195 Church Street (address) — Business Address
• New Haven (location) — Business Address City
• CT (location) — Business Address State
• 06510 (postal_code) — Business Address Zip

FAQ

Key Dates

• 2024-03-31: Quarterly Period End — Reporting period for the 10-Q filing.
• 2024-05-07: Filing Date — Date the 10-Q was officially filed with the SEC.
• 2021-10-18: Private Placement Event — Related to New Enterprise Associates 16 Limited Partnership.
• 2020-08-13: Silicon Valley Bank Term Loan — Date associated with a specific debt instrument.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share TRVI The Nasdaq

Filing Documents

• trvi-20240331.htm (10-Q) — 1849KB
• trvi-ex31_1.htm (EX-31.1) — 15KB
• trvi-ex31_2.htm (EX-31.2) — 15KB
• trvi-ex32_1.htm (EX-32.1) — 9KB
• trvi-ex32_2.htm (EX-32.2) — 9KB
• 0000950170-24-054489.txt (&nbsp;) — 7742KB
• trvi-20240331.xsd (EX-101.SCH) — 1110KB
• trvi-20240331_htm.xml (XML) — 1287KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 26 Item 1A.

Risk Factors

Risk Factors 26 Item 5. Other Information 68 Item 6. Exhibits 69

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Condensed Consolidated Financi al Statements

Item 1. Condensed Consolidated Financi al Statements. Trevi Therapeutics, Inc. Condensed Consolida ted Balance Sheets (Amounts in thousands, except share and per share amounts) March 31, 2024 December 31, 2023 Assets Unaudited Current assets: Cash and cash equivalents $ 13,811 $ 32,397 Marketable securities 59,009 50,574 Prepaid expenses 3,225 3,621 Other current assets 721 955 Total current assets 76,766 87,547 Operating lease right-of-use assets 1,084 1,137 Other non-current assets 311 297 Property, equipment and leasehold improvements, net 204 216 Finance lease right-of-use assets 194 206 Total assets $ 78,559 $ 89,403 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,112 $ 1,809 Accrued expenses 2,842 3,709 Operating lease liabilities 198 184 Finance lease liabilities 124 122 Total current liabilities 5,276 5,824 Operating lease liabilities 949 1,001 Finance lease liabilities — 31 Total liabilities 6,225 6,856 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock: $ 0.001 par value; 5,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 2023. — — Common stock: $ 0.001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; and 68,960,167 and 68,283,699 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively. 69 68 Additional paid-in capital 322,368 321,642 Accumulated other comprehensive loss ( 67 ) ( 29 ) Accumulated deficit ( 250,036 ) ( 239,134 ) Total stockholders' equity 72,334 82,547 Total liabilities and stockholders' equity $ 78,559 $ 89,403 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Trevi Therapeutics, Inc. Con

View Full Filing

View this 10-Q filing on SEC EDGAR